Q3 EPS Estimate for 4D Molecular Therapeutics Cut by Analyst

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimates for 4D Molecular Therapeutics from ($0.92) to ($1.01), reflecting a less optimistic outlook for the company’s earnings.
• The current consensus estimates suggest that 4D Molecular Therapeutics will report a full-year loss of ($2.84) per share for 2023, with predicted losses increasing in subsequent years.
• Despite negative earnings performance, the company's stock price recently increased by 8.5% and has received mixed ratings from analysts, including several "buy" ratings and one "sell".

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($1.01) per share for the quarter, down from their prior estimate of ($0.92). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($4.82) EPS, FY2028 earnings at ($5.00) EPS and FY2029 earnings at ($3.88) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%.

A number of other research firms also recently issued reports on FDMT. The Goldman Sachs Group cut their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Barclays cut their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Chardan Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Thursday, August 14th. Finally, Roth Capital lowered their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $30.40.

4D Molecular Therapeutics Stock Down 8.5%

Shares of 4D Molecular Therapeutics stock traded down $0.62 during trading hours on Thursday, reaching $6.65. 630,019 shares of the stock traded hands, compared to its average volume of 883,681. The company has a 50 day moving average price of $4.73 and a 200 day moving average price of $4.14. The firm has a market capitalization of $310.56 million, a price-to-earnings ratio of -1.88 and a beta of 2.83. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $17.41.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $39,000. Y Intercept Hong Kong Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $41,000. Los Angeles Capital Management LLC acquired a new stake in 4D Molecular Therapeutics during the second quarter worth about $42,000. Quadrature Capital Ltd acquired a new stake in 4D Molecular Therapeutics during the second quarter worth about $42,000. Finally, AQR Capital Management LLC acquired a new stake in 4D Molecular Therapeutics during the first quarter worth about $46,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.